Lesson plan

Envonalkib

Envonalkib is a pharmaceutical drug for cancer treatment. It belongs to the class of anaplastic lymphoma kinase inhibitors (ALK inhibitors). In China, it is approved for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not received treatment with ALK inhibitors.

Back to article

Article summary

Envonalkib is a pharmaceutical drug for cancer treatment. It belongs to the class of anaplastic lymphoma kinase inhibitors (ALK inhibitors). In China, it is approved for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not received treatment with ALK inhibitors.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.